Premium
The utility of the C‐peptide in the phenotyping of patients candidates for pancreas transplantation
Author(s) -
Esmatjes Enric,
Fernández Cristian,
Rueda Sergio,
Nicolau Juana,
Chiganer Gastón,
Ricart María José,
Junca Elizabet,
FernándezCruz Laureano
Publication year - 2007
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2007.00649.x
Subject(s) - medicine , type 1 diabetes , transplantation , diabetes mellitus , c peptide , pancreas transplantation , kidney transplantation , pancreas , type 2 diabetes , peptide , gastroenterology , endocrinology , biochemistry , chemistry
It is not unusual for simultaneous pancreas and kidney transplantation (SPK) to be performed in patients with type 2 diabetes (T2D), clinically classified as having type 1 diabetes (T1D). C‐peptide determination is useful to identify these patients. We describe the prevalence and characteristics of patients with C‐peptide levels >3 ng/mL, classified with T2D in 172 patients referred for SPK from 1998–2006. Nine patients (5.2%) fulfilled this criteria (mean free C‐peptide 9.08 ng/mL) and were older at diabetes onset (23.5 vs. 12 yr, p < 0.001) and at assessment (42.2 vs. 37.6 yr, p = 0.047) with shorter time between diabetes onset and renal failure (17.8 vs. 22.7 yr, p = 0.3) compared with T1D patients (mean free C‐peptide 0.24 ng/mL). In our experience the prevalence of T2D in candidates for SPK is not negligible. Despite some clinical differences with T1D these T2D patients can phenotypically be confounded with T1D in the absence of C‐peptide determination.